摘要
目的:探讨膀胱尿路上皮癌术后检测尿肝细胞生长因子(HGF)和核基质蛋白22(NMP22)表达水平在肿瘤复发监测中的临床价值。方法:2005年1月～2009年6月收治膀胱尿路上皮癌患者92例(接受TURBT或膀胱部分切除术者),术后2周开始规律性膀胱灌注化疗药物吡柔比星(THP)。采用酶联免疫吸附法(ELISA)分别检测灌注前、灌注6周、6个月和12个月时尿中HGF和NMP22的含量;对照组为31例健康人。结果:92例膀胱癌患者术后12个月有11例复发,复发率12%。未复发者尿HGF和NMP22含量随膀胱灌注时间的延长呈下降趋势,肿瘤复发时却明显升高,与对照组比较,差异有统计学意义(P<0.05);尿HGF、NMP22含量和尿脱落细胞学检查(VUC)对膀胱尿路上皮癌术后复发诊断的敏感性分别为91%、73%和45%,特异性分别为58%、48%和98%,阳性预测值分别为100%、80%和71.4%,阴性预测值分别为57%、48%和93%。结论:检测尿HGF和NMP22含量可以作为膀胱尿路上皮癌术后肿瘤复发监测及早期诊断的有效指标,二者结合具有较高的敏感性和预测性。
Objective：To evaluate clinical significance of Hepatocyte Growth Factor（HGF） and Nuclear Matrix Protein 22（NMP22） of voided urine tests in detecting the relapse of post-operative bladder cancer. Method： A total of 92 patients （males 79, females 13） with bladder cancer and 31 healthy volunteers enrolled in this study were classified into two groups： post-operative patients with bladder cancer were used pirarubicin（THP）; 31 heathly volunteers. The voided urine of all the patients in before, 6weeks, 6 months, 12 months post perfusion were re- covered selectively. HGF and NMP22 kits were used to detect bladder cancer. Voided urine cytology（VUC） was used to compare the sensitivity and specificity of the screening test. Result：There were 11 cases who relapsed in 92 patients with perfusion in 12 months. The level of HGF and NMP22 decreased with the prolong of perfusing time. There were mostly increased in the relapse of bladder cancer. The sensitivity and specificity of HGF, NMP22 and VUC were 91 ~//0, 73~//00, 450/oo and 58~/0, 48a//0, 98O//oo respectively. The VUC has the lowest sensitivity among the screening tests. The HGF and NMP22 with the sensitivity can be an adjunct to cytology for evaluating relapse of bladder cancer. Conclusion：The HGF and NMP22 test has a better correlation with the relapse of the bladder cancer. They might be promising tools for screening and early diagnosing bladder cancer.
出处
《临床泌尿外科杂志》
2012年第12期909-912,共4页
Journal of Clinical Urology
基金
天津市卫生局科研基金项目(编号04KY20)
